1. P686: A PHASE 1 FIRST IN-HUMAN STUDY OF BGB-16673, A BRUTON TYROSINE KINASE PROTEIN DEGRADER, IN PATIENTS (PTS) WITH B-CELL MALIGNANCIES (TRIAL IN PROGRESS). (23rd June 2022) Authors: Tam, C. S.; Cheah, C.; Stevens, D. A.; By, K.; Chen, X.; Tariq, B.; Vosganian, G. S.; Huang, J.; Alwan, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 582 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PB1890: ZANUBRUTINIB IN ACALABRUTINIB-INTOLERANT PATIENTS (PTS) WITH B-CELL MALIGNANCIES. (23rd June 2022) Authors: Shadman, M.; Flinn, I. W.; Kingsley, E. C.; Freeman, B.; Levy, M. Y.; Cultrera, J.; Farber, C. M.; Chaudhry, A.; Porter, R.; Crescenzo, R.; Idoine, A.; Zhang, X.; Cohen, A.; By, K.; Huang, J.; Sharman, J. P. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1769 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗